Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 21 full-time employees. The company went IPO on 2018-06-26. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Follow-Up Questions
Quelle est la performance du prix de l'action WHWK ?
Le prix actuel de WHWK est de $2.53, il a decreased de 4.88% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Whitehawk Therapeutics Inc ?
Whitehawk Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Whitehawk Therapeutics Inc ?
La capitalisation boursière actuelle de Whitehawk Therapeutics Inc est de $119.2M
Est-ce que Whitehawk Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Whitehawk Therapeutics Inc, y compris 0 achat fort, 0 achat, 5 maintien, 1 vente et 0 vente forte
